India · Delayed Price · Currency is INR Aarti Pharmalabs Statistics
Total Valuation
NSE:AARTIPHARM has a market cap or net worth of INR 58.23 billion. The enterprise value is 66.08 billion.
| Market Cap | 58.23B |
| Enterprise Value | 66.08B |
Important Dates
The last earnings date was Monday, May 25, 2026.
| Earnings Date | May 25, 2026 |
| Ex-Dividend Date | Feb 16, 2026 |
Share Statistics
NSE:AARTIPHARM has 90.66 million shares outstanding. The number of shares has increased by 0.07% in one year.
| Current Share Class | 90.66M |
| Shares Outstanding | 90.66M |
| Shares Change (YoY) | +0.07% |
| Shares Change (QoQ) | +0.04% |
| Owned by Insiders (%) | 29.64% |
| Owned by Institutions (%) | 18.47% |
| Float | 47.90M |
Valuation Ratios
The trailing PE ratio is 33.37 and the forward PE ratio is 36.09.
| PE Ratio | 33.37 |
| Forward PE | 36.09 |
| PS Ratio | 3.20 |
| PB Ratio | 2.74 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 22.23 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 16.10, with an EV/FCF ratio of -44.82.
| EV / Earnings | 37.82 |
| EV / Sales | 3.63 |
| EV / EBITDA | 16.10 |
| EV / EBIT | 21.59 |
| EV / FCF | -44.82 |
Financial Position
The company has a current ratio of 1.49, with a Debt / Equity ratio of 0.37.
| Current Ratio | 1.49 |
| Quick Ratio | 0.64 |
| Debt / Equity | 0.37 |
| Debt / EBITDA | 1.97 |
| Debt / FCF | -5.38 |
| Interest Coverage | 6.36 |
Financial Efficiency
Return on equity (ROE) is 8.49% and return on invested capital (ROIC) is 8.34%.
| Return on Equity (ROE) | 8.49% |
| Return on Assets (ROA) | 5.83% |
| Return on Invested Capital (ROIC) | 8.34% |
| Return on Capital Employed (ROCE) | 11.72% |
| Weighted Average Cost of Capital (WACC) | 6.20% |
| Revenue Per Employee | 8.42M |
| Profits Per Employee | 808,082 |
| Employee Count | 2,162 |
| Asset Turnover | 0.57 |
| Inventory Turnover | 1.36 |
Taxes
In the past 12 months, NSE:AARTIPHARM has paid 582.14 million in taxes.
| Income Tax | 582.14M |
| Effective Tax Rate | 24.99% |
Stock Price Statistics
The stock price has decreased by -29.49% in the last 52 weeks. The beta is 0.40, so NSE:AARTIPHARM's price volatility has been lower than the market average.
| Beta (5Y) | 0.40 |
| 52-Week Price Change | -29.49% |
| 50-Day Moving Average | 688.93 |
| 200-Day Moving Average | 759.60 |
| Relative Strength Index (RSI) | 37.13 |
| Average Volume (20 Days) | 236,433 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, NSE:AARTIPHARM had revenue of INR 18.19 billion and earned 1.75 billion in profits. Earnings per share was 19.25.
| Revenue | 18.19B |
| Gross Profit | 9.85B |
| Operating Income | 2.98B |
| Pretax Income | 2.33B |
| Net Income | 1.75B |
| EBITDA | 4.02B |
| EBIT | 2.98B |
| Earnings Per Share (EPS) | 19.25 |
Balance Sheet
The company has 96.16 million in cash and 7.94 billion in debt, with a net cash position of -7.84 billion or -86.49 per share.
| Cash & Cash Equivalents | 96.16M |
| Total Debt | 7.94B |
| Net Cash | -7.84B |
| Net Cash Per Share | -86.49 |
| Equity (Book Value) | 21.25B |
| Book Value Per Share | 234.27 |
| Working Capital | 4.60B |
Cash Flow
In the last 12 months, operating cash flow was 2.62 billion and capital expenditures -4.09 billion, giving a free cash flow of -1.47 billion.
| Operating Cash Flow | 2.62B |
| Capital Expenditures | -4.09B |
| Depreciation & Amortization | 1.04B |
| Net Borrowing | 2.46B |
| Free Cash Flow | -1.47B |
| FCF Per Share | -16.26 |
Margins
Gross margin is 54.12%, with operating and profit margins of 16.38% and 9.60%.
| Gross Margin | 54.12% |
| Operating Margin | 16.38% |
| Pretax Margin | 12.80% |
| Profit Margin | 9.60% |
| EBITDA Margin | 22.12% |
| EBIT Margin | 16.38% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.50, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | 3.50 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | 14.29% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 20.75% |
| Buyback Yield | -0.07% |
| Shareholder Yield | 0.48% |
| Earnings Yield | 3.00% |
| FCF Yield | -2.53% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |